Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR plus breast cancer: A secondary analysis of the SOFT trial.

被引：0
|
作者：
Brown, Lauren Claire
Luen, Stephen James
Molania, Ramyar
Caramia, Franco
Savas, Peter
VanGeelen, Courtney
Chic, Nuria
Fleming, Gini F.
Kammler, Rosita
Colleoni, Marco
Viale, Giuseppe
Speed, Terence Paul
Regan, Meredith M.
Francis, Prudence A.
Loi, Sherene
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Univ Chicago, Chicago, IL USA
[3] Int Breast Canc Study Grp, Bern, Switzerland
[4] European Inst Oncol, Milan, Italy
[5] Univ Milan, European Inst Oncol, Milan, Italy
[6] Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia
[7] Dana Farber Canc Inst, Boston, MA USA
[8] Int Breast Canc Study Grp, Boston, MA USA
[9] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
澳大利亚国家健康与医学研究理事会;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
504
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Clinical impact of differential risk stratification by breast cancer index (BCI) versus recurrence score (RS) in HR plus early-stage breast cancer: A TransATAC study.
    Sestak, Ivana
    Zhang, Yi
    Schnabel, Catherine A.
    Schroeder, Brock
    Ander, Mark Er
    Goss, Paul E.
    Cuzick, Jack M.
    Dowsett, Mitchell
    Sgroi, Dennis
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors
    Zohra, M. Fatma
    ANNALS OF ONCOLOGY, 2023, 34 : S1099 - S1099
  • [23] Comparison of PAM50 risk of recurrence (ROR) scores with EndoPredict for predicting risk of distant metastasis in ER+/HER2-, early node-positive breast cancer patients treated with adjuvant chemotherapy - A GEICAM/ 9906 sub-study
    Martin, M.
    Brase, J. C.
    Perou, C. M.
    Ruiz, A.
    Prat, A.
    Weber, K. E.
    Calvo, L.
    Petry, C.
    Bernard, P. S.
    Ruiz-Borrego, M.
    Kronenwett, R.
    Santaballa, A. M.
    Rodriguez, C. A.
    Alvarez, I. M.
    Segui, M. A.
    Casas, M.
    Carrasco, E.
    Caballero, R.
    Rodriguez-Lescure, A.
    CANCER RESEARCH, 2013, 73
  • [24] Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR plus ) early breast cancer (BC): Analysis of the SOFT trial
    Goldhirsch, Aron
    Gelber, Richard D.
    Francis, Prudence A.
    Regan, Meredith M.
    Fleming, Gini F.
    Lang, Istvan
    Ciruelos, Eva M.
    Bellet, Meritxell
    Bonnefoi, Herve
    Climent, Miguel A.
    Pavesi, Lorenzo
    Burstein, Harold J.
    Martino, Silvana
    Davidson, Nancy E.
    Geyer, Charles E., Jr.
    Walley, Barbara A.
    Coleman, Robert E.
    Kerbrat, Pierre
    Rabaglio-Poretti, Manuela
    Coates, Alan S.
    CANCER RESEARCH, 2015, 75
  • [25] Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial
    Gluz, Oleg
    Kolberg-Liedtke, Cornelia
    Prat, Aleix
    Christgen, Matthias
    Gebauer, Daniel
    Kates, Ronald
    Pare, Laia
    Grischke, Eva-Maria
    Forstbauer, Helmut
    Braun, Michael
    Warm, Mathias
    Hackmann, John
    Uleer, Christoph
    Aktas, Bahriye
    Schumacher, Claudia
    Kuemmel, Sherko
    Wuerstlein, Rachel
    Pelz, Enrico
    Nitz, Ulrike
    Kreipe, Hans Heinrich
    Harbeck, Nadia
    INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (01) : 262 - 271
  • [26] Pam50 intrinsic subtype and risk of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) in the alternate trial (Alliance A011106)
    Ma, Cynthia X.
    Anurag, Meenakshi
    Dockter, Travis
    Hoog, Jeremy
    Fernandez-Martinez, Aranzazu
    Fan, Cheng
    Gibbs, Richard
    Sanati, Souzan
    Vij, Kiran
    Watson, Mark
    Hahn, Olwen
    Guenther, Joseph
    Caudle, Abigail
    Crouch, Erika
    Tiersten, Amy
    Mita, Monica
    Razaq, Wajeeha
    Hieken, Tina J.
    Wang, Yang
    Leitch, A. Marilyn
    Unzeitig, Gary W.
    Weiss, Anna
    Winer, Eric P.
    Hunt, Kelly
    Partridge, Ann H.
    Carey, Lisa A.
    Perou, Charles M.
    Ellis, Matthew J.
    Suman, Vera
    CANCER RESEARCH, 2022, 82 (04)
  • [27] Tamoxifen versus tamoxifen plus octreotide LAR as adjuvant therapy for early-stage breast cancer in postmenopausal women: Update of NCIC CTG MA14 trial.
    Pollak, M. N.
    Chapman, J. W.
    Pritchard, K. I.
    Krook, J. E.
    Dhaliwal, H. S.
    Vandenberg, T. A.
    Whelan, T. J.
    O'Reilly, S. E.
    Wilson, C. F.
    Shepherd, L. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer
    Laenkholm, Anne-Vibeke
    Jensen, Maj-Britt
    Eriksen, Jens Ole
    Rasmussen, Birgitte Bruun
    Knoop, Ann S.
    Buckingham, Wesley
    Ferree, Sean
    Schaper, Carl
    Nielsen, Torsten O.
    Haffner, Taryn
    Kibol, Torben
    Talman, Maj-Lis Moller
    Jylling, Anne Marie Bak
    Tabor, Tomasz Piotr
    Ejlertsen, Bent
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) : 735 - +
  • [29] Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR plus ), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET)
    Eriksen, J. Ole
    Jensen, M-B
    Laenkholm, A-V
    Kiboll, T.
    Rasmussen, B. Bruun
    Knoop, A. S.
    Ferree, S.
    Haffner, T.
    Buckingham, W.
    Schaper, C.
    Ejlertsen, B.
    CANCER RESEARCH, 2016, 76
  • [30] Prediction of late distant recurrence (DR) using the Prosigna (PAM50) test in a Danish Breast Cancer Cooperative Group (DBCG) cohort of postmenopausal women diagnosed with hormone receptor-positive (HR plus ) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET).
    Laenkholm, Anne-Vibeke
    Jensen, Maj-Britt
    Eriksen, Jens Ole
    Kiboll, Torben
    Rasmussen, Birgitte Bruun
    Knoop, Ann S.
    Ferree, Sean
    Haffner, Taryn
    Schaper, Carl
    Ejlertsen, Bent
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345